Skip to main content
Fig. 3 | Stem Cell Research & Therapy

Fig. 3

From: Multipotent mesenchymal stromal cells from patients with newly diagnosed type 1 diabetes mellitus exhibit preserved in vitro and in vivo immunomodulatory properties

Fig. 3

T1D-MSCs efficiently inhibit in vitro T-cell proliferation. In coculture assays, different concentrations of phytohemagglutinin (PHA)-stimulated allogeneic peripheral blood mononuclear cells (PBMCs) labeled with CFSE were cultured in the presence of C-MSCs (n = 6) or T1D-MSCs (n = 3). The percentage of CD3+ T-lymphocyte proliferation was determined by flow cytometry. a Percentages of lymphocyte proliferation. b Percentages of lymphocyte proliferation inhibition. Data expressed as mean ± SD. C-MSCs mesenchymal stromal cells from bone marrow of healthy individuals, MSC multipotent mesenchymal stromal cell, T1D-MSCs mesenchymal stromal cells from bone marrow of newly diagnosed T1D patients

Back to article page